BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $111.00

Key Points

• JPMorgan raised BridgeBio Pharma’s price target to $111 from $100 and maintained an “overweight” rating, implying 32.73% upside from the prior close.
• Analyst sentiment remains favorable, with 20 Buy, two Hold and one Sell rating; the consensus is “Moderate Buy” with a $100.42 price target.
• BridgeBio’s latest revenue rose 120.4% year over year to $243.68 million, beating estimates, but its $0.78-per-share loss exceeded analyst expectations.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) had its price target lifted by equities researchers at JPMorgan Chase & Co. from $100.00 to $111.00 in a report released on Wednesday,Benzinga reports. The brokerage presently has an "overweight" rating on the stock. JPMorgan Chase & Co.'s price objective suggests a potential upside of 32.73% from the stock's previous close.

BBIO has been the subject of several other research reports. Piper Sandler increased their price objective on shares of BridgeBio Pharma from $111.00 to $115.00 and gave the company an "overweight" rating in a report on Tuesday. Wells Fargo & Company lifted their target price on BridgeBio Pharma from $98.00 to $102.00 and gave the stock an "overweight" rating in a report on Tuesday. Canaccord Genuity Group started coverage on BridgeBio Pharma in a research report on Wednesday, June 3rd. They issued a "buy" rating and a $104.00 target price on the stock. Truist Financial increased their price target on BridgeBio Pharma from $95.00 to $102.00 and gave the company a "buy" rating in a research note on Wednesday, April 29th. Finally, Citigroup raised their price target on BridgeBio Pharma from $82.00 to $93.00 and gave the company a "neutral" rating in a report on Thursday, July 16th. Twenty equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $100.42.

BridgeBio Pharma Stock Performance

Shares of BridgeBio Pharma stock traded down $0.07 on Wednesday, hitting $83.63. 87,369 shares of the company traded hands, compared to its average volume of 2,986,128. BridgeBio Pharma has a 52 week low of $46.81 and a 52 week high of $93.42. The business has a 50-day simple moving average of $76.47 and a 200 day simple moving average of $73.07. The stock has a market capitalization of $16.35 billion, a P/E ratio of -23.41 and a beta of 0.96.

BridgeBio Pharma (NASDAQ:BBIO - Get Free Report) last issued its earnings results on Monday, August 10th. The company reported ($0.78) earnings per share for the quarter, missing analysts' consensus estimates of ($0.58) by ($0.20). The company had revenue of $243.68 million for the quarter, compared to analysts' expectations of $220.91 million. The business's revenue was up 120.4% compared to the same quarter last year. During the same period last year, the company posted ($0.95) EPS. Research analysts expect that BridgeBio Pharma will post -2.31 earnings per share for the current year.

Insider Activity

In other BridgeBio Pharma news, Director Jennifer E. Cook sold 148,589 shares of the business's stock in a transaction that occurred on Thursday, July 9th. The stock was sold at an average price of $88.54, for a total transaction of $13,156,070.06. Following the completion of the transaction, the director owned 8,383 shares in the company, valued at $742,230.82. The trade was a 94.66% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Thomas Trimarchi sold 13,651 shares of the stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $65.08, for a total value of $888,407.08. Following the completion of the sale, the chief financial officer owned 359,194 shares in the company, valued at approximately $23,376,345.52. The trade was a 3.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 392,117 shares of company stock worth $29,934,700 in the last 90 days. Company insiders own 14.23% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Jones Financial Companies Lllp bought a new stake in BridgeBio Pharma during the 1st quarter valued at about $35,000. First Trust Advisors LP increased its position in shares of BridgeBio Pharma by 200.4% during the second quarter. First Trust Advisors LP now owns 263,693 shares of the company's stock worth $11,386,000 after acquiring an additional 175,918 shares during the period. Baird Financial Group Inc. raised its stake in shares of BridgeBio Pharma by 1.8% during the second quarter. Baird Financial Group Inc. now owns 42,057 shares of the company's stock valued at $1,816,000 after acquiring an additional 731 shares in the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main bought a new stake in shares of BridgeBio Pharma during the second quarter valued at approximately $1,650,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of BridgeBio Pharma by 2.4% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 95,326 shares of the company's stock valued at $4,132,000 after purchasing an additional 2,206 shares during the period. 99.85% of the stock is currently owned by institutional investors.

BridgeBio Pharma News Summary

Here are the key news stories impacting BridgeBio Pharma this week:

• Positive Sentiment: Second-quarter revenue rose 120.4% year over year to $243.68 million, beating the $220.91 million consensus estimate. Growth was led by Attruby, whose U.S. net sales reportedly increased 311%, while ex-U.S. Beyonttra royalties also improved. BridgeBio Q2 Earnings Miss, Revenues Beat as Attruby Sales Surge
• Positive Sentiment: Management reaffirmed guidance for more than $1 billion in 2026 global Attruby and Beyonttra sales and expects three product launches by mid-2027. A $1 billion preferred-equity financing also strengthens the balance sheet and supports commercial and pipeline investment. BridgeBio: Attruby Delivers In Q2, Expect Three New Launches In 12 Months
• Positive Sentiment: Analysts raised their valuation targets: Piper Sandler to $115, TD Cowen to $110, Bank of America to $104, and Wells Fargo to $102, with each maintaining a positive rating. Morgan Stanley made a smaller reduction to $97 but retained its overweight rating.
• Neutral Sentiment: BridgeBio was highlighted among biotech companies with potentially important second-half 2026 catalysts, including regulatory decisions and late-stage clinical readouts. 4 Biotech Stocks With Major Second-Half Pipeline Catalysts This Year
• Negative Sentiment: Adjusted quarterly loss was $0.78 per share, worse than the approximately $0.58–$0.64 analyst expectations, although it improved from a $0.95 loss a year earlier. The earnings shortfall is likely the main source of near-term selling pressure.
• Negative Sentiment: BridgeBio granted restricted stock units covering 66,705 shares to 56 new employees. The routine hiring-related awards may create limited shareholder dilution. BridgeBio Pharma Reports Inducement Grants

About BridgeBio Pharma

BridgeBio Pharma, Inc is a clinical-stage biopharmaceutical company headquartered in Palo Alto, California. Founded in 2015 by Neil Kumar, the company is dedicated to discovering, developing and delivering transformative medicines for patients with genetic diseases and cancers. BridgeBio operates an integrated model that spans target identification, preclinical research, clinical development and commercialization, aiming to streamline the process from bench to bedside.

BridgeBio's pipeline comprises multiple therapeutic modalities, including small molecules, biologics and genetic therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source